Trial Profile
Impact of pazopanib on Metastatic Renal Cell Carcinoma patients' health-related quality of life in the US community oncology setting.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 24 May 2018 New trial record
- 23 May 2018 Results presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research